BioDuro-Sundia, an Advent International portfolio company is a trusted, leading contract research development, manufacturing organization (CRDMO) for over 27 years. We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US and China with more than 3,000 employees and 10 global sites across 7 cities.
Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The one stop shop operation helps biotech and pharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes. We adhere to one global highest standard of compliance and business operation code. Science-driven, customer-oriented, flexible, people focused culture enables us to provide top-tier integrated, fast and flexible tailored services to our customers to meet their unique needs and accelerate development timeline.
Dr. Kent M. Payne is distinguished as a business operator and leader in areas of sales, commercial manufacturing and product development. He has extensive executive experience in M&A as well as successfully running, start up, growth and turn around businesses. This includes both Fortune 500 and Private Equity environments. Dr. Payne combines strong business leadership, successful P&L track record, and technical background to strategically lead and grow enterprise value across Biotechnology and Pharmaceutical market segments. In addition to the United States，he has also successfully led the geographic expansion of businesses into Europe, Asia, and South America. Dr. Payne currently serves as CEO for BioDuro-Sundia, LLC (an Advent International company) and also serves as a board member for Goodwin Biotechnologies (a Signet Healthcare company).
Dr. Li has led a distinguished career in the pharmaceutical industry, having spent over 18 years at various companies including Henkel, Wyeth, Pfizer and Wuxi Apptec in the area of process research and medicinal chemistry. During his career, he was involved in numerous drug discovery programs such as COPD, asthma, Rheumatoid/osteoarthritis, and diabetes. Dr. Li has co-authored more than 60 research articles and patents.
Dr. Li received his Ph.D in Organic Chemistry from University of Central Lancashire UK followed by a Postdoctoral fellow at the University of Chicago with Dr. Philip Eaton.
Ms. Lisa Ren has over 16 years of experience in sales, business development and client management across life sciences industries. She joined BioDuro-Sundia in 2012 and has helped the company build a strong customer base and network including pharmaceuticals, biotech, universities, research institutions, government and regulatory agencies. Prior to growing into the role as Vice President of Business Development APAC, Lisa has built up a strong BD team as the Head of Business Development APAC, delivering sales milestone after sales milestone for the company over the past ten years, making great contributions to its outstanding business success.
Prior to joining BioDuro-Sundia, Lisa worked at Fluke Cooperation and Bridge Laboratories for 6 years. She graduated from Beijing Normal University with M.S. degree in Education and B.S degree in Business Management.
Roy has over 25 years of healthcare industry experience. He started his career as an orthopedic surgeon. Roy joined Eli Lilly as a sales rep in 1997. Since then he has had various roles in market research, business intelligence, BU head, strategy, regional general management, business development etc., both at Eli Lilly and Boehringer Ingelheim (BI). Roy also spent more than two years in Germany where he was BI’s Director of Corporate Business and Enabling Strategy.
Roy obtained a bachelor’s degree in Clinical Medicine at Zhejiang Traditional Chinese Medicine University, and an MBA from Zhejiang University.
Michel Blanc did study organic chemistry and chemical engineering at Ecole Centrale de Marseille in France. He brings over 18 years of experience in servicing Pharmaceutical companies. He held global Business Development responsibilities and was part of the management team at well established Drug Substance and Drug Product CDMOs or APIs producers (Avecia (now part of Piramal), NextPharma, Novasep, Seqens or Pharmazell).
Michel was also a board member of the French fine chemical industry association (SICOS Biochimie) and of the French CDMO association (SPIS now CDMO France).
David Preston has had 38 years of healthcare experience with publicly Traded and Private companies in the fields of Pharmaceuticals, Animal Health and Biotechnology as a Board Member. The last 30 years of his experience has been in China, Taiwan and Hong Kong building successful high growth businesses. David Has been Chairman and CEO for Greater China for Sanofi and Boehringer – Ingelheim as well as the Janssen Corporation since 1991 in China. During this time he build high Growth businesses in China through diversified strategies in Innovative Pharmaceuticals. branded Generics. Biotechnology. and Animal Healthcare.
Key highlights in this period included building of the first Westen Multinational Biotechnology C.M.O. facility as well as obtaining the first Test CM.OJ MAHI license. Establishment of a number of High tech Vaccine Plants, and R and D facilities in in the field of Animal Health. Signing and development of numerous JV’s as well as Wholly owned Subsidiaries. Mergers and Acquisitions across Pharmaceutical’s. Animal Health. and Biotechnology industries.
David’s achievement’s in the Healthcare industry and it Growth and development in China is widely recognized By the Chinese Government and the City of Shanghai In 2013 he was awarded the Silver Magnolia allowed in 2015 the Gold Magnolia award. This was then followed by being awarded in 2017 the Honorary Citizen of Shanghai by 40th People’s Municipal Congress of Shanghai. David Holds a Business Science Degree.
Andrew Li joined Advent in 2012. He previously worked at Warburg Pincus, HSBC PE, Solera Capital and Credit Suisse where he focused on the retail and consumer, healthcare, industrial, and energy sectors. Andrew has worked in finance and private equity throughout the U.S. and China since 1999. Andrew holds a BA from Middlebury College and an MBA from Harvard Business School.
Michael Miltenberger joined Advent in 2011 as an associate on the healthcare team. Following business school, he rejoined Advent’s Boston office, focusing on healthcare investments. Prior to Advent, Michael was a consultant at McKinsey & Company in their Washington DC office, serving a range of healthcare and private equity clients. Michael earned a BA, cum laude, from Harvard College and an MBA from Harvard Business School, graduating with High Distinction as a Baker Scholar and a Harvey Fellow.
Dr. Masood Tayebi is the Founder of BioDuro. He currently serves as CEO of a nationwide real estate portfolio and is a Partner and Chief Executive Officer of the Bridgewest Group. Prior to BioDuro, Dr. Tayebi was Co-Founder and Chairman of Wireless Facilities, Inc. (NASDAQ: WFI), a global leader in telecommunications outsourcing.
Cathy joined the Board of Directors of BioDuro-Sundia in 2020, with the Advent-led acquisition of Sundia and creation of BioDuro-Sundia. Prior to that, she was Chairman of the Board at Sundia Meditech Group, where she was the key architect of Sundia’s strategic vision and growth. Under her leadership, Sundia solidified its position as one of the leading pre-clinical CROs in China.
Prior to Sundia, Cathy had a distinguished career as a seasoned venture capitalist, having led numerous investments in high-growth companies in Asia. Cathy served as a Partner of AsiaVest Partners, TCW/YFY Ltd., a global venture capital firm, for over a decade, Vice President at Global Financial Services, Vice President at Crimson Ventures/Chinatrust Bank and Senior Manager at Fortune Capital. She brings over 20 years of experience in corporate finance, accounting, strategic planning and private equity investments.
Amit Patel has twenty years of healthcare industry experience with publicly-traded, private equity-backed, and start-up companies in the capacity of executive, board member, advisor, and investor. He is currently Executive Chairman of Azurity Pharmaceuticals (a NovaQuest Capital Management portfolio company) and a board member at BioDuro (Advent International portfolio company), Tergus Pharma (Great Point Partners portfolio company) and Calyptus Pharma. Recently, Amit was SVP & President of Dosage Form Solutions at Capsugel, a KKR portfolio company (purchased from Pfizer in 2011 and sold to Lonza in 2017).
Prior to Capsugel, he worked at Dr. Reddy’s Laboratories, Inc. as EVP & Head of North America, and SVP & Head of Global Corporate Development & Strategic Planning. Earlier, Amit was VP of Corporate Development at CTIS, Inc., and Co-founder & CEO of MedOnTime, Inc. (acquired by CTIS). He started his career as a strategy consultant with Marakon Associates. Amit holds an M.B.A. degree from Harvard Business School, a B.S. degree in Economics from the Wharton School of Business, University of Pennsylvania, and a B.A.S. degree in Systems Engineering from the Moore School of Engineering, University of Pennsylvania.
Acquired two US-based commercial drug product manufacturing facilities with over 100,000 sq. ft. and 4 billion doses capacity annually
Completed 1st GMP drug product manufacturing at new R&D center in Wuxi
Acquired Sundia to become BioDuro-Sundia, one of the largest CRDMOs worldwide
300,000 sq. ft. Wuxi facility opened with integrated capabilities across discovery and GMP manufacturing
Advent bought majority of stake and partnered with BioDuro
Acquired Molecular Response (“Tumor Bank”)
BioDuro reacquired from PPD; BioDuro and Formex merged to enable broad range of service offering
Formex joined Bridgewest Group, operating in a 44,000 sq. ft. GMP facility
93,000 sq. ft. Shanghai facility (72,000 sq. ft. lab) opened to meet growing client demand
BioDuro acquired by PPD
Sundia merged with United Pharma
100,000 sq. ft. Beijing site opened –first site in China
BioDuro founded in San Diego by Biotech Investment Group with operations commenced in Beijing
At BioDuro-Sundia, we operate with integrity and strict standards of law and business ethics, which are our fundamental guidelines in all locations. We adhere the business ethics of legal compliance, integrity and self-discipline, and strictly comply with laws and regulations related to corporate governance and the Corporate Governance Code, and have zero tolerance for any form of corruption. We have built a strong security infrastructure that protects and preserves the intellectual property and data of our customers; We are implementing green manufacturing and sustainable operations across our business units, helping to improve the environment and our communities.